The Bottom Fishing Club: Campbell's 7.7x EV/EBITDA Is More Than Interesting
Campbell's Company trades near industry-low EV/EBITDA multiples, making it an attractive takeover target. GLP-1 medicine-driven declines in processed food sales and high debt have pressured CPB's profits and share price since 2022. CPB's 7.7x trailing and 8x forward EV/EBITDA ratios are compelling, especially if a recession or bear market emerges in 2026.